Skip to main content
. 2010 May 31;18(3):153–159. doi: 10.1016/j.jsps.2010.05.001

Table 5.

Robustness study for the developed method (n = 5).

Parameter studied Salmeterol xinafoate
Fluticasone propionate
SDa CVa SDa CVa
Composition of mobile phase 130.4 1.49 358.9 2.3
Volume of mobile phase 127.8 1.46 344.3 2.21
Time from spotting to development (5–60 min) 55.29 0.63 256.8 1.65
Time from development to scanning (5–60 min) 40.9 1.1 22.2 0.40
a

SD and CV were calculated from the peak areas of densitograms.